Christina Amitrano considers herself lucky that her breast cancer was discovered at the age of 35. So after two years of aggressive treatment, she enrolled in a clinical trial of an experimental vaccine doctors hope will reduce the risk of her cancer's recurrence. Stony Brook Cancer Center is one of 160 sites worldwide participating in the FLAMINGO-01 Phase III clinical trial by Greenwich LifeSciences, a biopharmaceutical company based in Texas. It’s a tumor vaccine specific for people diagnosed with HER2-positive breast cancer. Read the full story at the link in bio. (Photos: John Paraskevas) - - #longislandny #stonybrook #cancer #breastcancer #vaccine